ClinicalTrials.gg
Drug

Gallium 68 PSMA-11 clinical trials

Also written 68Ga-PSMA-11 and DFKZ 11.

studies test it
63
open now
11
in phase 3
13
first study started
2015

How each study uses gallium 68 PSMA-11 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the gallium 68 PSMA-11 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

68Ga-PSMA
13
Gallium Ga 68-labeled PSMA-11
9
68Ga-HBED-CC-PSMA
6
Heidelberg compound
5
Ga-68 labeled DKFZ-PSMA-11
5

Brand

ProstaMedix
1
Locametz
1

Development codes

DFKZ 11
5
AAA517
1

Other names

68Ga-PSMA-11
15
Gallium Ga 68 Gozetotide
8
Ga-68 PSMA-11
1
(68Ga)PSMA-HBED-CC
1
68Ga-PSMA-HBED-CC
1
(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC
1
Gallium Ga-68 gozetotide
1
Gallium (68Ga) gozetotide
1

Studies by the year they started

63 studies that test it; most in 2020 (11)

Studies that test gallium 68 PSMA-11, by start year
YearStudies
20154
20165
20176
20185
20196
202011
20219
20226
20231
20244
20252
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
9
Phase 1
9
Phase 2
36
Phase 3
13
No phase
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 4 · Other 59

Mayo Clinic (7) · Andrei Iagaru (5) · Thomas Hope (4) · Jonsson Comprehensive Cancer Center (4) · Peking Union Medical College Hospital (4) · University of California, San Francisco (3) · First Affiliated Hospital of Fujian Medical University (3) · Novartis Pharmaceuticals (2)

Often tested with

Tested in the same studies.

Rm-2 ga-68 (5) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (1) · PSMA-1007 F-18 (1) · Sodium Glutamate (1) · Fluciclovine F-18 (1) · 89Zr-Df-IAB2M (1) · 68 Ga-P16-093 (1) · Vipivotide tetraxetan gallium GA-68 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test gallium 68 PSMA-11, phase 3 first.

Studies

Open first, then newest update. How each study uses gallium 68 PSMA-11 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 63

See all 63 studies that test gallium 68 PSMA-11 →

Given beside what is tested · 10 — gallium 68 PSMA-11 is usual care or a partner of the new treatment

Codes

What other systems call gallium 68 PSMA-11 · ClinicalTrials.gg INT001668

  • MeSH (NLM) C000718244gallium 68 PSMA-11One source ClinicalTrials.gov
  • UNII (FDA) ZJ0EKR6M10GALLIUM GA-68 GOZETOTIDEConfirmed FDA, Wikidata
  • RxNorm 2586016One source FDA
  • Wikidata Q27295602gallium 68 PSMA-11Confirmed FDA, Wikidata
  • DrugBank DB16019One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.